Robert Giugliano, MD, is a senior investigator with the TIMI Study Group, staff physician in the Cardiovascular Division at Brigham and Womenâ€™s Hospital, and associate professor of medicine at Harvard Medical School. Dr. Giuglianoâ€™s areas of research interest include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes. He has authored more than 200 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the principal investigator for the ENGAGE-AF TIMI 48 trial, and a member of the Operations Committees and lead TIMI investigator for the IMPROVE-IT, FOURIER, and EARLY ACS trials. 

Evolocumab substantially improves survival in high-risk patients without a prior 

, according to a new subanalysis of VESALIUS-CV.

Evolocumab Improves Survival in Patients Without Prior MI or Stroke

European Society of Cardiology (ESC) Congress 2026

 in Munich, Germany, by Robert Giugliano, MD, professor of medicine at Harvard Medical School and a physician at Brigham & Women’s Hospital.

“If you start a cholesterol-lowering medicine today, you’re not going to prevent a death tomorrow, or in a week, or in a month, or even in a year. It takes a while. You’re affecting the underlying pathology,” Giugliano told 

in an exclusive interview. “You’re changing the plaque, but it takes a while for that to translate into a reduction in death. So, we have to treat patients for a lifetime.”

The original VESALIUS-CV trial was an international, double-blind, randomized, placebo-controlled trial across 774 sites in 33 countries. Patients were eligible for inclusion if they were 50-79 years of age in men or 55-79 years of age in women and had an LDL-C level of ≥90 mg/dL, a non-HDL-C level of ≥120 mg/dL, or an apolipoprotein B level ≥80 mg/dL. Additionally, patients were required to be on stable, optimized lipid-lowering therapy for ≥2 weeks.

Patients were assigned in a 1:1 ratio to either evolocumab 140 mg every 2 weeks or matching placebo. The 2 primary efficacy endpoints were a composite of death from coronary heart disease, MI, or ischemic stroke (3-point major adverse cardiovascular event [MACE]) and a composite of 3-point MACE and ischemia-driven arterial revascularization. Secondary endpoints included each individual component and composites of pairs of each component.

A total of 12,257 patients were assigned to receive either evolocumab (n = 6129) or placebo (n = 6128), with a median age of 66 years and 43% women. After a median follow-up of 4.6 years, 3-point MACE events occurred in 336 patients in the evolocumab group and 443 in the placebo group (HR, 0.75; 95% CI, 0.65-0.86; 

 <.001), and 4-point MACE events occurred in 747 patients in the evolocumab group versus 907 in the placebo group (HR, 0.81; 95% CI, 0.73-0.89; 

The present study was a prespecified secondary analysis of the VESALIUS-CV trial, incorporating all 12,257 patients from the original trial. Giugliano and colleagues evaluated the effects of evolocumab for all-cause mortality and cause-specific death, including cardiovascular disease, non-cardiovascular disease, and deaths of undetermined etiology. Cardiovascular death was further subcategorized as acute MI, sudden cardiac death, heart failure, cardiovascular hemorrhage, cardiovascular procedures, or other cardiovascular causes.

During the 4.6-year follow-up, 973 patients died. Patients who died were more likely to be older at baseline with a higher prevalence of high-risk diabetes and kidney dysfunction. Of the 973 deaths, 351 (36%) were adjudicated as attributable to cardiovascular causes, 497 (51%) were non-cardiovascular, and 125 (13%) were of undetermined cause. The most frequent causes of cardiovascular death were sudden cardiac death (n = 174), heart failure (n = 58), acute MI (n = 44), and stroke (n = 39), representing 50%, 17%, 13%, and 11% of all cardiovascular deaths, respectively.

Evolocumab nominally reduced the rate of all-cause mortality by 20% - among the evolocumab group, 434 patients died (5-year Kaplan-Meier rate, 7.9%), compared to 539 deaths in the placebo arm (9.7%) (HR, 0.8; 95% CI, 0.7-0.91; 

 = .0005). There was no reduction in mortality endpoints in the first 1.5 years (HR, 0.99; 95% CI, 0.78-1.25), according to landmark analyses; this was followed by a 27% reduction thereafter (HR, 0.73; 95% CI, 0.63-0.85).

Giugliano and colleagues ultimately concluded that these data support the use of evolocumab to improve survival in patients without prior MI or stroke, particularly among those with high-risk diabetes without qualifying atherosclerosis. However, the implementation of this treatment, Giugliano acknowledges, will likely face the same limitations as other lipid-lowering therapies.

“A large gap in background treatment of hyperlipidemias persists even in patients at high risk, patients who have known, diagnosed coronary disease, or cerebrovascular disease, or peripheral arterial disease, or high-risk diabetes,” Giugliano said. “We need to do a better job at reducing LDLs across the board, particularly in those patients at high risk.”

Editors’ Note: Giugliano reports disclosures from Amgen, Daiichi-Sankyo, Inventiva Pharma, Novartis, Pfizer, Sanofi, and others.

Giugliano RP, Bohula EA, Bellavia A, et al. Effects of evolocumab on mortality outcomes in patients without previous myocardial infarction or stroke: A prespecified analysis of the VESALIUS-CV randomized clinical trial. Circulation. Published online August 31, 2026. 

Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial infarction or stroke. New England Journal of Medicine. 2026;394(2):117-127. 

Videos

Robert Giugliano, MD, breaks down his prespecified subanalysis of the VESALIUS-CV trial, evaluating evolocumab’s effect on cardiovascular mortality.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Michael Wechsler, MD, of National Jewish Health.

Verekitug, an investigational monoclonal antibody that targets the thymic stromal lymphopoietin (TSLP) receptor, met its primary endpoint in the phase 2 VALIANT trial, reducing annualized 

 exacerbation rates by as much as 56% overall and 87% in patients with elevated eosinophil counts. The results, from Upstream Bio's ongoing development program in severe asthma, were presented at the 

European Respiratory Society (ERS) Congress 2026

"Even low concentrations of verekitug are sufficient to saturate the TSLP receptors, and therefore abrogate some of the TSLP signaling, and this allows for longer dosing intervals," Michael Wechsler, MD, MMSc, professor of medicine and director of the Cohen Family Asthma Institute at National Jewish Health, said in an interview with HCPLive.

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD

TSLP is an upstream epithelial alarmin that drives activation of interleukin-4, interleukin-5, and interleukin-13 through T helper 2 cells and ILC2 cells, playing a central role in the type 2 inflammatory pathways implicated in asthma and chronic sinusitis with nasal polyps (CRSwNP). While other therapies, including tezepelumab, target TSLP itself, verekitug is the only agent in development that targets the TSLP receptor directly. Wechsler noted that the added benefit is an extended half-life alongside a robust efficacy signal, building on what he described as an already well-validated pathway.

VALIANT was a multicenter, randomized, placebo-controlled phase 2 trial that enrolled 478 adults with poorly controlled asthma, defined by an Asthma Control Questionnaire (ACQ) score >1.5, along with either 2 exacerbations or 1 emergency department visit with inpatient care in the prior year, or 1 exacerbation plus an exhaled nitric oxide level >50. All participants required a medium to high dose inhaled corticosteroid for at least 3 months prior to enrollment. Patients were randomized to 1 of 3 verekitug doses, 100 mg every 12 weeks, 400 mg every 24 weeks, or 100 mg every 24 weeks, or to placebo. The primary outcome was the annualized asthma exacerbation rate through week 60, with a minimum of 24 weeks of drug exposure required; median exposure across the trial was approximately 37 weeks.

Baseline ACQ-6 scores ranged from 2.5 to 2.7, with eosinophil counts between 250 and 290 cells/microliter and lung function near 60%. The placebo arm had an annualized exacerbation rate of approximately 1.52, while all 3 verekitug doses produced statistically significant and clinically meaningful reductions, ranging from 39% to 56%, independent of phenotype. The effect was more pronounced among patients with eosinophil counts ≥300 cells/microliter.

"In the patients who had high eosinophil counts, there was an 87% reduction in exacerbations. This is really exciting. It's best in class as far as I'm concerned, for demonstrating a reduction in exacerbations," Wechsler said. Patients with eosinophil counts <150 cells/microliter, who represent roughly 20% of the severe asthma population, did not show a significant reduction. Verekitug also improved forced expiratory volume in 1 second (FEV1), with 100 to 157 mL gains at 6 months, along with improvements in ACQ scores and exhaled nitric oxide levels.

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD

Editor’s Note: Wechsler reports relevant disclosures with Upstream Bio and is principal investigator on the VALIANT trial.

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma. GlobeNewswire. February 11, 2026. 

https://www.globenewswire.com/news-release/2026/02/11/3236073/0/en/Upstream-Bio-Reports-Positive-Top-line-Results-from-the-Phase-2-VALIANT-Trial-of-Verekitug-for-the-Treatment-of-Severe-Asthma.html

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026. GlobeNewswire. September 8, 2026. 

https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Kristina Duffin, MD, MS is a professor in the Department of Dermatology and recently appointed Dean of the Spencer Fox Eccles School of Medicine at the University of Utah.

Dermatologists increasingly step into administrative and health system leadership roles despite limited formal leadership training during residency or fellowship.

LEADderm, founded and chaired by Jennifer Soung, MD, was built to close this gap, prioritizing skills such as mentorship, negotiation, and practice building over traditional clinical programming.¹ The 2026 meeting convened dermatologists, physician associates, and nurse practitioners in Newport Beach, California, for 2 days of leadership-focused sessions.¹

Kristina Duffin, MD, MS, is professor of dermatology and dean of the Spencer Fox Eccles School of Medicine at the University of Utah. She built her session, "Lessons in Leadership: Elements & Experiments," around the framework from the book Total Leadership.² She examined what qualities and behaviors leaders bring to four areas of life: work, home, spiritual or personal life, and community.

She described physician leaders taking on new roles beyond clinical care, including chief problem solver, chief vision setter, and chief cultural attaché. Duffin outlined a three-question framework for delegation: whether a task belongs only to the leader, whether someone else would benefit from solving it as sponsorship or mentorship, or whether it falls outside the leader's role.

She pointed to professional coaching and leadership courses, including programs from the American Academy of Dermatology and Intermountain Health, as ways to build these relational skills. "You cannot do CPR and run the code at the same time," said Duffin, describing how leaders must learn which problems are truly theirs to solve.

In the following Q&A discussion, Duffin sat down with 

 at LEADderm 2026 in Newport Beach, California, to discuss the elements and experiments behind her leadership journey:

: Why did you choose ‘Lessons in Leadership: Elements and Experiments’ as your LEADderm topic?

 I wanted to share a little of my story about my journey to leadership, because I think there are misconceptions about how people become leaders. Sometimes it's not that intentional, and you have to learn a lot about your own skills and strengths as you move into it. I wanted to knit together some of the elements I found valuable in leadership, as well as the experiments that resulted from that.

: What were the main takeaways from your session?

 A lot of what we've been talking about today at LEADderm has been about personal resilience, well-being, building community, and how to speak in a way that commands a room, many different individual skills. What I felt I needed to start with was what qualities, traits, or elements are necessary for my own thriving in leadership. I've read many books about leadership, and one of my favorites is called Total Leadership, which asks what qualities, traits, or behaviors you should bring to all four aspects of your life: work life, home life, spiritual or self life, and community. That's an exploration for every leader to have. From there, I looked at how to deploy those things in being a leader: being the chief problem solver, the chief vision setter, and the chief cultural attaché.

: What's one tip from the talk that's most worthwhile for clinicians to take away?

 Health care providers are leaders in their own right. They're leading their teams, and they're leading their patients toward better health decisions, so leaders are always made in health care. As you move up, whether you become a vice chair, a chair, or a dean, you're going to be asked to solve problems, and the most important thing you can do at that point is ask: is this my problem to solve? Define that as carefully as you can. The slogan I brought was a quote from a colleague of mine from many years ago: you cannot do CPR and run the code at the same time. As a leader, the things you were doing before change. You might not see as many patients, or you might do supervision and education to help people become better physicians.

: Is knowing when to take charge versus delegate key for budding leaders in dermatology?

 Absolutely. There are three questions to ask: Is this something only I can do in my current role? If so, that's your job. Or is this something someone else would be better at solving? Maybe they're becoming a leader themselves, and giving them that problem helps them; that's sponsorship. Or you help them solve it; that's mentorship. The last option is that it's not your job at all. The risk of doing someone else's job is that you're taking time you shouldn't be devoting to it anymore, and you might damage the relationship. People generally don't want you to do their job for them.

: What tips do you have for clinicians who want to step into leadership roles but aren't there yet?

 The most critical activity I did early on, when I was moving toward leadership, was coaching. Having a professional coach who's good at pointing out your blind spots helps you understand how to be individualistic and yet still be part of a community and a team. Those skills aren't necessarily things you're born with; they can be learned, taught, and absorbed. I recommend individual coaches, or leadership courses like this one at LEADderm, as well as courses offered by the American Academy of Dermatology and other organizations. Intermountain Health, for example, offers one focused on exploring the personal qualities and traits of leadership rather than how to balance a spreadsheet or understand health care economics. It's about relational leadership traits, and those are very valuable.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Duffin had no relevant financial disclosures of note.

Smith T. Conference Preview: 2026 LEADderm Conference in Newport Beach, CA. HCPLive. Published August 27, 2026. Accessed September 11, 2026. 

https://www.hcplive.com/view/conference-preview-2026-leadderm-conference-newport-beach-ca

University of Utah Health. Kristina Callis Duffin, MD, MS, Named Dean of the Spencer Fox Eccles School of Medicine at the University of Utah. Published April 1, 2026. Accessed September 11, 2026. 

https://healthcare.utah.edu/press-releases/2026/04/kristina-callis-duffin-md-ms-named-dean-of-spencer-fox-eccles-school-of

Articles

Dermatology clinicians are increasingly expected to lead teams and health systems, yet formal leadership training remains uncommon. LEADderm was created to fill this gap with programming centered on mentorship, negotiation, practice development, and relational skills. Kristina Duffin applied the Total Leadership framework to align leadership behaviors across work, home, self/spiritual life, and community, framing senior roles as chief problem solver, vision setter, and cultural attaché. She emphasized disciplined delegation, recognizing which problems belong to the leader, and using coaching and structured courses to uncover blind spots.

Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q&A: Lessons in Leadership from LEADderm 2026, With Kristina Duffin, MD

Guy Brusselle, MD, PhD, of Ghent University Hospital.

A significantly greater proportion of patients with 

severe chronic rhinosinusitis with nasal polyps (CRSwNP)

 achieved composite asthma clinical remission at week 24 with dupilumab (Dupixent) than with omalizumab (Xolair), according to an analysis of the phase 4 EVEREST trial presented at the 

European Respiratory Society (ERS) 2026 Congress

EVEREST is the first head-to-head trial comparing 2 approved biologics in this overlapping upper and lower airway population.

 Topline efficacy results were published in 

 in December 2025, and the new analysis extends those findings by evaluating a composite asthma remission endpoint incorporating exacerbations, oral corticosteroid (OCS) use, lung function stability, and symptom control.

Guy Brusselle, MD, PhD, of Ghent University Hospital in Belgium, discussed the trial design and findings with 

“Although the active comparator is not [a] placebo but an active treatment, omalizumab, the dupilumab-treated group has a more profound benefit, and the difference between these 2 active treatments is above the MCID, the minimal clinically important difference,” Brusselle said. “So, [these are] very intriguing results.”

Dupilumab Outperforms Omalizumab for Asthma Remission in phase 4 EVEREST

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST

Dupilumab Achieves Greater Asthma Clinical Remission Rates in EVEREST

EVEREST randomized 360 adults with severe CRSwNP and coexisting asthma of any severity 1:1 to subcutaneous dupilumab 300 mg every 2 weeks (n = 181) or weight- and IgE-tiered omalizumab 75-600 mg every 2 or 4 weeks (n = 179) for 24 weeks, on a background of inhaled corticosteroids, intranasal corticosteroids, and a second asthma controller.

 Patients were stratified by type 2 inflammatory status, defined as baseline eosinophils of ≥ 150 cells/µL or fractional exhaled nitric oxide of ≥ 25 ppb. Mean age was 52 years, with a mean 13-year duration of CRSwNP and adult-onset asthma beginning around age 35 years, Bruselle said.

In the prespecified remission analysis, patients were classified by whether they met a composite asthma clinical remission endpoint at week 24, defined as absence of asthma-related exacerbations, no OCS use, stable or improved FEV1 (≤ 5% decline from baseline), and an Asthma Control Questionnaire-5 (ACQ-5) score of ≤ 1.5.

 A significantly greater percentage of dupilumab-treated patients met all 4 criteria compared with omalizumab, at 64% (112 of 175) versus 40.5% (70 of 173) (

Nasal Polyp Score, Smell, and Lung Function Outcomes in EVEREST


EVEREST is a phase 4, head-to-head trial comparing dupilumab and omalizumab in adults with severe CRSwNP and coexisting asthma over 24 weeks, including a composite asthma clinical remission endpoint at week 24.

How did dupilumab compare with omalizumab for asthma clinical remission?


In the week 24 analysis, 64.0% of dupilumab-treated patients met composite asthma clinical remission criteria versus 40.5% of omalizumab-treated patients (

Did nasal polyp and smell outcomes differ by remission status?


No; dupilumab produced greater improvement in nasal polyp score and UPSIT scores than omalizumab regardless of whether patients met asthma clinical remission criteria at week 24.²

Regardless of whether patients met remission criteria, dupilumab produced greater improvement than omalizumab in objective upper airway measures. Bruselle said that nasal polyp score fell by nearly 3 points with dupilumab compared with roughly 1 point with omalizumab at week 24 (P <.0001) University of Pennsylvania Smell Identification Test scores improved to a significantly greater extent with dupilumab as well (

The pattern extended to lower airway outcomes. Dupilumab produced a more pronounced increase in pre-bronchodilator FEV1 than omalizumab, and SNOT-22 scores improved more with dupilumab as well. ACQ-7 scores declined by nearly 2 points with dupilumab versus approximately 1.5 points with omalizumab, with the treatment difference exceeding the minimal clinically important difference for the outcome, Bruselle said.

The full EVEREST dataset, including additional lung function parameters, was presented separately at the 2025 CHEST Annual Meeting, reinforcing dupilumab's comparative benefit across large and small airway outcomes in this population.³ Under the trial's protocol, clinical asthma remission is only confirmed once criteria are sustained through week 52, and longer-term follow-up is anticipated.

Brusselle G, Heffler E, Busse WW, et al. Clinical asthma remission and nasal polyp outcomes over 24 weeks with dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and uncontrolled asthma: results from EVEREST. Presented at: European Respiratory Society (ERS) Congress 2026; September 5-9, 2026; Barcelona, Spain.

De Corso E, Canonica GW, Heffler E, et al. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. 

Kunzmann K. Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma. HCPLive. 

https://www.hcplive.com/view/dupilumab-bests-omalizumab-airway-improvement-patients-crswnp-asthma

. Published October 22, 2025. Accessed September 11, 2026.

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Sadiya Khan, MD, MSc, is the Magerstadt Professor of Cardiovascular Epidemiology, associate professor of medicine, preventive medicine, and medical social sciences, and the director of the Center for Population Science and Aging at Northwestern University Feinberg School of Medicine.

Artificial intelligence (AI) is a burgeoning technology, developing rapidly across a wide range of industries. Now that it is beginning to make itself known in 

 care, many clinicians have begun to shift their focus from how the technology is implemented to the question of equity and ethical usage.

Equitable and Ethical AI Use in Cardiology: Addressing Biases and Privacy Concerns

 in Munich, Germany, chaired by Sadiya Khan, MD, MSc, the Magerstadt Professor of Cardiovascular Epidemiology, associate professor of medicine, preventive medicine, and medical social sciences, and the director of the center for population science and aging at Northwestern University Feinberg School of Medicine, a series of presentations discussed the ethical and practical pathways for AI implementation in cardiovascular care – as well as addressing the potential roadblocks and pitfalls inherent in this new technology.

“One of the key things that came up in this session – in every single person’s presentation – was that AI has become such a buzzword, and we are all enamored by the opportunity,” Khan told 

 in an exclusive interview. “It is of course going to be used, and it is being used, and it should be better implemented because we want to maximize the impact we can have on patient outcomes. The challenge is how we do it, and whether or not it makes things better.”

Although cardiovascular disease accounts for roughly 50% of all mortality in the United States, access to care and advanced therapies are reduced for Black, Indigenous, rural, and lower-income individuals. Additionally, these groups tend to have a higher likelihood of heart failure, stroke, and hypertension. AI’s rapid expansion in recent years has presented the opportunity to bridge these gaps in care access.

However, AI in itself is also prone to disparities in access and potential inequity. Generative AI, such as the large language models (LLMs) that are increasingly used to collate and interpret medical data, can easily inherit biases and contextual issues from the data used to train them.

In a review from August 2026, investigators from the University of Pittsburgh and the Cohen Children’s Heart Center in New York analyzed these biases and developed a series of design principles for the creation of equitable generative AI. In particular, they highlighted representation bias, in which case the AI’s training data does not accurately reflect the target population, and deployment bias, when the AI is implemented in a different context from the one for which it was originally designed.

Additionally, the presence of AI in healthcare is an intrinsically thorny issue in terms of patient privacy. These models are trained on and work with substantial amounts of sensitive data, including imaging, genetic information, and patient history. Without proper security, these data could be vulnerable to unauthorized access or breaches. This issue was a key focus in several of the presentations in Khan’s session, and largely remains an open question for clinicians.

“Patient privacy is really one of the core things in medicine, and we hold it very dearly – AI threatens the ability of continuing to protect data,” Khan said. “If it is unleashed without guardrails, without clear stopgaps that need to be in place, it has the potential to do that. I think that’s probably one of the key things we need to figure out: who has governance over the data, and how can we maximize their impact in a way that doesn’t threaten patient privacy?”

Editors’ Note: Khan reports no relevant disclosures.

Kulkarni A, Visweswaran S. Achieving equity in generative artificial intelligence in cardiovascular medicine. JACC: Advances. 2026;5(8):102967. 

Göçer H, Durukan AB. The potential risks of artificial intelligence in cardiovascular care. Turk Gogus Kalp Damar Cerrahisi Derg. 2025;33(2):262-264. Published 2025 Apr 30. 

Sadiya Khan, MD, MSc, discusses the session she chaired at ESC 2026, which saw clinicians discuss the equitability of artificial intelligence in medicine.

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD

Ann Falsey, MD, is a professor of Medicine at the University Of Rochester School Of Medicine. The focus of her research has been clinical and translational research in the field of respiratory viral infections in adults.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction

Mohammad Ali Salehinejad, PhD, from the department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at RWTH Aachen University.

Mohammad Ali Salehinejad, PhD, explains how template-based targeting could extend optimized multichannel tDCS to broader clinical and home-based care.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Multichannel tDCS Shows Path to Scalable Use in MDD

Oyvind Lie, MD, PhD, MSc, is a senior consultant in interventional cardiology at Oslo University Hospital in Norway.

Oyvind Lie, MD, PhD, MSc, discusses the results from the ACASA-TAVI trial, which sought to evaluate the efficacy of anticoagulant monotherapy in this population.

Anticoagulant Monotherapy Reduces Thrombosis, Improves Bleeding After TAVI

Peter Lio, MD, breaks down AdvanceAD-Tx testing and oral STAT6 degrader KT-621 in the atopic dermatitis pipeline.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Q&A: Precision Medicine's Next Steps in Atopic Dermatitis, With Peter Lio, MD

Jose Nicolau, MD, PhD, is a professor at the University of São Paulo Medical School and senior investigator at the Heart Institute InCor.

Jose Nicolau, MD, PhD, discusses the results of his subanalysis of the VESALIUS-CV trial, examining secondary rather than first MACE.

Evolocumab Prevents Recurrent Cardiovascular Events Following MI or Stroke

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Tirzepatide's New CV Indication and the STAREE Statin Trial 

"Byron Wade is a principal consultant at American Healthcare Strategies and co-founder of the Wade Family Foundation. He has more than 20 years of clinical and administrative healthcare experience, including leading physician recruitment strategy for UPMC.

A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Diagnosis to Data: What Patient Experience Adds to IgAN Research

Peter Lio, MD, discusses SKiN Angels dermatology investing and AI's growing role in patient care and clinician education.

Q&A: SKiN Angels and AI's Growing Role in Dermatology, With Peter Lio, MD

A study found 4 mA multichannel tDCS achieved a 75% MDD response rate versus 45% for conventional 2 mA stimulation, Mohammad Ali Salehinejad, PhD, says.

Latest News

Evolocumab Improves Survival in Patients Without Prior MI or Stroke

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD

Q&A: Lessons in Leadership from LEADderm 2026, With Kristina Duffin, MD

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST

Equitable and Ethical AI Use in Cardiology: Addressing Biases and Privacy Concerns